Abstract
Introduction: In 2015, directional leads have been released in Europe for deep brain stimulation (DBS) and have been particularly used for subthalamic nucleus (STN) DBS for Parkinson’s disease (PD). In this study, we aimed to compare an omnidirectional and directional leads cohort of PD patients when it comes to clinical effectiveness and to assess the correlation with volume of tissue activated-target overlap (VTA-target). Methods: A total of 60 consecutive patients were retrospectively included. Twenty-seven patients with bilateral directional leads were compared to 33 patients with bilateral omnidirectional leads. MDS-UPDRS part III scores, levodopa equivalent daily dose (LEDD), and VTA overlaps using both motor STN region and motor improvement sweet spot volume were compared at 12 months after surgery. Results: There is a significantly higher LEDD reduction in the directional leads group (51.3% reduction vs. 42.7% reduction, p = 0.042) when compared to the omnidirectional group, with similar MDS-UPDRS III motor scores at 12 months. Omnidirectional leads patients had a significantly superior VTA-motor STN overlap volume than directional leads patients (32.01 mm3 vs. 20.38 mm3, p = 0.0226). In directional leads patients, LEDD reduction was correlated to VTA overlap with the overall motor improvement mean map sweet spot (R = 0.36, p = 0.036), which was not the case for omnidirectional leads patients (R = 0.11, p = 0.276). Forty-one percent of patients implanted with directional leads had a directional stimulation setting at 12 months, compared to 33% at 3 months follow-up. In directional leads patient’s subgroup analysis, there was no significant difference in MDS UPDRS III scores, LEDD reduction, VTA overlaps with motor STN, or overall motor improvement mean map sweet spot between patients stimulated omnidirectionally and directionally at 12 months. Conclusion: At 12 months, when compared to omnidirectional leads, directional leads manage with smaller VTA-target overlaps to obtain comparable MDS-UPDRS III scores with greater LEDD reduction in STN DBS for PD patients.
Journal Section:
Clinical Study
References
1.
Benabid
AL
, Chabardes
S
, Mitrofanis
J
, Pollak
P
. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease
. Lancet Neurol
. 2009
;8
(1
):67
–81
. 2.
Odekerken
VJJ
, van Laar
T
, Staal
MJ
, Mosch
A
, Hoffmann
CFE
, Nijssen
PCG
, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial
. Lancet Neurol
. 2013
;12
(1
):37
–44
. 3.
Chou
KL
, Taylor
JL
, Patil
PG
. The MDS–UPDRS tracks motor and non–motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson disease
. Parkinsonism Relat Disord
. 2013
;19
(11
):966
–9
. 4.
Floden
D
, Cooper
SE
, Griffith
SD
, Machado
AG
. Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation
. Neurology
. 2014
;83
(18
):1627
–33
. 5.
Lagrange
E
, Krack
P
, Moro
E
, Ardouin
C
, Van Blercom
N
, Chabardes
S
, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD
. Neurology
. 2002
;59
(12
):1976
–8
. 6.
Fraix
V
, Houeto
JL
, Lagrange
C
, Le Pen
C
, Krystkowiak
P
, Guehl
D
, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease
. J Neurol Neurosurg Psychiatry
. 2006
;77
(4
):443
–9
. 7.
Bove
F
, Mulas
D
, Cavallieri
F
, Castrioto
A
, Chabardès
S
, Meoni
S
, et al. Long-term outcomes (15 Years) after subthalamic nucleus deep brain stimulation in patients with Parkinson disease
. Neurology
. 2021
;97
(3
):e254
–62
. 8.
Emmi
A
, Antonini
A
, Macchi
V
, Porzionato
A
, De Caro
R
. Anatomy and connectivity of the subthalamic nucleus in humans and non-human primates
. Front Neuroanat
. 2020
;14
:13
. 9.
Martinez-Fernandez
R
, Castrioto
A
, Krack
P
. Prefrontal: STN projections, the highway for emotion and cognition control
. Mov Disord
. 2014
;29
(3
):305
. 10.
Albin
RL
, Young
AB
, Penney
JB
. The functional anatomy of basal ganglia disorders
. Trends Neurosci
. 1989
;12
(10
):366
–75
. 11.
de Roquemaurel
A
, Wirth
T
, Vijiaratnam
N
, Ferreira
F
, Zrinzo
L
, Akram
H
, et al. Stimulation sweet spot in subthalamic deep brain stimulation: myth or reality? A critical review of literature
. Stereotact Funct Neurosurg
. 2021
;99
(5
):425
–42
. 12.
Umemura
A
, Oka
Y
, Yamamoto
K
, Okita
K
, Matsukawa
N
, Yamada
K
. Complications of subthalamic nucleus stimulation in Parkinson’s disease
. Neurol Med Chir
. 2011
;51
(11
):749
–55
. 13.
Guo
T
, Parrent
AG
, Peters
TM
. Surgical targeting accuracy analysis of six methods for subthalamic nucleus deep brain stimulation
. Comput Aided Surg
. 2007
;12
(6
):325
–34
. 14.
Schüpbach
WMM
, Chabardes
S
, Matthies
C
, Pollo
C
, Steigerwald
F
, Timmermann
L
, et al. Directional leads for deep brain stimulation: opportunities and challenges
. Mov Disord
. 2017
;32
(10
):1371
–5
. 15.
Masuda
H
, Shirozu
H
, Ito
Y
, Fukuda
M
, Fujii
Y
. Surgical strategy for directional deep brain stimulation
. Neurol Med Chir
. 2022
;62
(1
):1
–12
. 16.
Kramme
J
, Dembek
TA
, Treuer
H
, Dafsari
HS
, Barbe
MT
, Wirths
J
, et al. Potentials and limitations of directional deep brain stimulation: a simulation approach
. Stereotact Funct Neurosurg
. 2021
;99
(1
):65
–74
. 17.
Steigerwald
F
, Müller
L
, Johannes
S
, Matthies
C
, Volkmann
J
. Directional deep brain stimulation of the subthalamic nucleus: a pilot study using a novel neurostimulation device
. Mov Disord
. 2016
;31
(8
):1240
–3
. 18.
Dembek
TA
, Reker
P
, Visser-Vandewalle
V
, Wirths
J
, Treuer
H
, Klehr
M
, et al. Directional DBS increases side-effect thresholds-A prospective, double-blind trial
. Mov Disord
. 2017
;32
(10
):1380
–8
. 19.
Schnitzler
A
, Mir
P
, Brodsky
MA
, Verhagen
L
, Groppa
S
, Alvarez
R
, et al. Directional deep brain stimulation for Parkinson’s disease: results of an international crossover study with randomized, double-blind primary endpoint
. Neuromodulation
. 2022
;25
(6
):817
–28
. 20.
Pintér
D
, Járdaházi
E
, Balás
I
, Harmat
M
, Makó
T
, Juhász
A
, et al. Antiparkinsonian drug reduction after directional versus omnidirectional bilateral subthalamic deep brain stimulation
. Neuromodulation
. 2023
;26
(2
):374
–81
. 21.
Verber
D
, Novak
D
, Borovič
M
, Dugonik
J
, Flisar
D
. EQUIDopa: a responsive web application for the levodopa equivalent dose calculator
. Comput Methods Programs Biomed
. 2020
;196
:105633
. 22.
Horn
A
, Li
N
, Dembek
TA
, Kappel
A
, Boulay
C
, Ewert
S
, et al. Lead-DBS v2: towards a comprehensive pipeline for deep brain stimulation imaging
. Neuroimage
. 2019
;184
:293
–316
. 23.
Friston
KJ
, editor. Statistical parametric mapping: the analysis of funtional brain images
. 1st ed. Amsterdam ; Boston
: Elsevier/Academic Press
; 2007
. p. 647
.24.
Avants
BB
, Epstein
CL
, Grossman
M
, Gee
JC
. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain
. Med Image Anal
. 2008
;12
(1
):26
–41
. 25.
Schönecker
T
, Kupsch
A
, Kühn
AA
, Schneider
GH
, Hoffmann
KT
. Automated optimization of subcortical cerebral MR imaging-atlas coregistration for improved postoperative electrode localization in deep brain stimulation
. AJNR Am J Neuroradiol
. 2009
;30
(10
):1914
–21
. 26.
Fonov
V
, Evans
AC
, Botteron
K
, Almli
CR
, McKinstry
RC
, Collins
DL
, et al. Unbiased average age-appropriate atlases for pediatric studies
. Neuroimage
. 2011
;54
(1
):313
–27
. 27.
Horn
A
, Kühn
AA
. Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations
. Neuroimage
. 2015
;107
:127
–35
. 28.
Husch
A
, V Petersen
M
, Gemmar
P
, Goncalves
J
, Hertel
F
. PaCER: a fully automated method for electrode trajectory and contact reconstruction in deep brain stimulation
. Neuroimage Clin
. 2018
;17
:80
–9
. 29.
Dembek
TA
, Hellerbach
A
, Jergas
H
, Eichner
M
, Wirths
J
, Dafsari
HS
, et al. DiODe v2: unambiguous and fully-automated detection of directional DBS lead orientation
. Brain Sci
. 2021
;11
(11
):1450
. 30.
Horn
A
, Reich
M
, Vorwerk
J
, Li
N
, Wenzel
G
, Fang
Q
, et al. Connectivity Predicts deep brain stimulation outcome in Parkinson disease
. Ann Neurol
. 2017
;82
(1
):67
–78
. 31.
Nowacki
A
, Nguyen
TAK
, Tinkhauser
G
, Petermann
K
, Debove
I
, Wiest
R
, et al. Accuracy of different three-dimensional subcortical human brain atlases for DBS –lead localisation
. Neuroimage Clin
. 2018
;20
:868
–74
. 32.
Dembek
TA
, Roediger
J
, Horn
A
, Reker
P
, Oehrn
C
, Dafsari
HS
, et al. Probabilistic sweet spots predict motor outcome for deep brain stimulation in Parkinson disease
. Ann Neurol
. 2019
;86
(4
):527
–38
. 33.
Koss
AM
, Alterman
RL
, Tagliati
M
, Shils
JL
. Calculating total electrical energy delivered by deep brain stimulation systems
. Ann Neurol
. 2005
;58
(1
):168
; author reply 168–169. 34.
Hui
D
, Murgai
AA
, Gilmore
G
, Mohideen
SI
, Parrent
AG
, Jog
MS
. Assessing the effect of current steering on the total electrical energy delivered and ambulation in Parkinson’s disease
. Sci Rep
. 2020
;10
(1
):8256
. 35.
Liang
K
, Li
RP
, Gao
Y
, Liu
C
, Wang
Q
, Gao
DM
, et al. Emotional symptoms and cognitive function outcomes of subthalamic stimulation in Parkinson’s disease depend on location of active contacts and the volume of tissue activated
. CNS Neurosci Ther
. 2023
;29
(8
):2355
–65
. 36.
Nguyen
TAK
, Djilas
M
, Nowacki
A
, Mercanzini
A
, Schüpbach
M
, Renaud
P
, et al. Analysis of patient-specific stimulation with segmented leads in the subthalamic nucleus
. PLoS One
. 2019
;14
(6
):e0217985
. 37.
Eleopra
R
, Rinaldo
S
, Devigili
G
, Lettieri
C
, Mondani
M
, D’Auria
S
, et al. Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients
. Clin Neurophysiol
. 2019
;130
(9
):1562
–9
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
